加载中
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
前收盘价
US$5.74
−US$0.44 · -7.12%
盘后
US$5.6503
−US$0.0897 · -1.56%
10月8日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日内区间
当前US$5.74
52周区间
当前US$5.74
盘中时间采用ET。市场数据可能有所延迟。
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
日内区间
当前US$5.74
52周区间
当前US$5.74
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 2499万 USD | 973万 USD |
| 销货成本 | 638.1万 USD | — | — | — | — |
| 毛利 | −638.1万 USD | — | — | 2499万 USD | 973万 USD |
| 研究与开发 | 9912.7万 USD | 9932.3万 USD | 1.06亿 USD | 7124.6万 USD | 4894.3万 USD |
| 销售、一般及管理费用 | 2298.7万 USD | 2829.2万 USD | 2653.3万 USD | 2629.5万 USD | 2222万 USD |
| 营业费用 | 1.16亿 USD | 1.28亿 USD | 1.52亿 USD | 9754.1万 USD | 7116.3万 USD |
| 利息收入 | 577.7万 USD | 1071.4万 USD | 997.8万 USD | 376万 USD | 9.1万 USD |
| 利息支出 | 3.6万 USD | 4000 USD | 2.5万 USD | 8万 USD | 17.6万 USD |
| 折旧和摊销 | 638.1万 USD | 646.8万 USD | 609.8万 USD | 266.7万 USD | 153.8万 USD |
| 营业利润 | −1.22亿 USD | −1.28亿 USD | −1.52亿 USD | −7255.1万 USD | −6143.3万 USD |
| 净利润 | −1.17亿 USD | −1.17亿 USD | −1.43亿 USD | −6979万 USD | −6199.9万 USD |
公司数据更新于 2026年10月9日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI211.61万0.00%2.3万亿 USD0.03%US$379.56-0.39%
Vanguard Extended Market ETFVXF86.05万0.00%954亿 USD0.05%US$233.13-0.15%
iShares Micro-Cap ETFIWC14.02万0.01%13.19亿 USD0.60%US$182.79-0.31%
Dimensional - US Small Cap ETFDFAS11.51万0.00%336.6亿 USD0.31%US$78.10+0.23%
U.S. Micro Cap Portfolio ETFDFMC10.71万0.00%75.2亿 USD0.43%US$57.70+0.35%
Avantis U.S. Small Cap Equity ETFAVSC4.08万—30.38亿 USD0.25%US$69.96+0.47%
U.S. Vector Equity Portfolio ETF Class SharesDXUV2954.040.00%61.57亿 USD0.26%US$68.11+0.22%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAvantis U.S. Small Cap Equity ETFAVSCU.S. Vector Equity Portfolio ETF Class SharesDXUVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
